Ramipril
- Generic Name
- Ramipril
- Brand Names
- Altace, Altace HCT
- Drug Type
- Small Molecule
- Chemical Formula
- C23H32N2O5
- CAS Number
- 87333-19-5
- Unique Ingredient Identifier
- L35JN3I7SJ
- Background
Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure...
- Indication
For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high ...
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hearth Failure With Reduced Ejection Fraction (HFrEF), Hypertension, Myocardial Infarction, Nondiabetic proteinuric chronic kidney disease, Stroke, High risk cardiovascular event
- Associated Therapies
- -
Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting Conditions
- Conditions
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 39
- Registration Number
- NCT00702091
- Locations
- 🇺🇸
CEDRA Clinical Research, LLC, Austin, Texas, United States
The Effect of Renin Angiotensin System Blockage (RAS) Blockade On PTX3 Levels In Diabetic Patients With Proteinuria
- Conditions
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2008-05-08
- Lead Sponsor
- Gulhane School of Medicine
- Target Recruit Count
- 60
- Registration Number
- NCT00674596
- Locations
- 🇹🇷
Gulhane School of Medicine, Ankara, Turkey
Gene Expression Profiling in Skeletal Muscle of Healthy Subjects Treated With Ramipril
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2011-08-22
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 18
- Registration Number
- NCT00657865
- Locations
- 🇦🇹
Medical University Vienna, Department of Clinical Pharacology, Vienna, Austria
A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 774
- Registration Number
- NCT00631917
- Locations
- 🇪🇸
Investigative Site, Investigative Site, Spain
The RAS, Fibrinolysis and Cardiopulmonary Bypass
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 111
- Registration Number
- NCT00607672
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸TN Valley Healthcare System, Nashville, Tennessee, United States
Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 4
- Registration Number
- NCT00608465
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 17
- Registration Number
- NCT00574834
- Locations
- 🇺🇸
University of Maryland, Baltimore, Baltimore, Maryland, United States
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2011-05-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 178
- Registration Number
- NCT00542269
- Locations
- 🇬🇧
Addenbrookes Hospital, Cambridge, United Kingdom
Nephropathy In Type 2 Diabetes and Cardio-renal Events
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 850
- Registration Number
- NCT00535925
- Locations
- 🇮🇹
Department of Advanced Medical and Surgical Sciences, Università della Campania "Luigi Vanvitelli", Naples, Italy, Naples, Italy
Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2011-03-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1613
- Registration Number
- NCT00529451
- Locations
- 🇹🇭
Novartis Investigative Sites, Thailand, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.